Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness

New Treatment Option for Second-Stage African Sleeping Sickness: In Vitro and In Vivo Efficacy of Aza Analogs of DB289

(2009) T. Wenzler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Predictive Models for Carcinogenicity and Mutagenicity: Frameworks, State-of-the-Art, and Perspectives

(2009) E. BENFENATI et al.   JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS

NECT trial: more than a small victory over sleeping sickness

(2009) Jimmy Opigo et al.   LANCET

Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

(2009) Gerardo Priotto et al.   LANCET

Human African trypanosomiasis

(2009) Reto Brun et al.   LANCET

Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis

(2008) J.K. Thuita et al.   ACTA TROPICA

Principles of Safety Pharmacology

(2008) M K Pugsley et al.   BRITISH JOURNAL OF PHARMACOLOGY

A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes

(2008) Shane R. Wilkinson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next?

(2008) Pere P Simarro et al.   PLOS MEDICINE

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL